Table 1 provides detailed clinical baseline data for patients in each group. Patients with HCC in the CS-positive group displayed statistically significant differences from the CS-negative group (P<0.05, Table 1) in gender, tumor size, MVI, BCLC stage, macrovascular invasion, liver cirrhosis, albumin, absolute neutrophil count (NEUT), the absolute number of eosinophils (EO), and absolute lymphocyte count (LYMPH). Comparing the HBV-positive and HBV-negative groups reveals statistically significant differences in age, cirrhosis, ALT, AST, and AFP (P 0.05, Table 1). This evidence concerns the gene GPT and hepatocellular carcinoma.